ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Vaccine approaches capable of eliciting enhanced germinal center (GC) responses would result in improved protective humoral immunity against infectious diseases. Here, we investigate whether a cytokine can be scaffolded onto a self-assembling nanoparticle immunogen to enhance antigen-specific GC responses and B cell maturation. To test this approach, we design chimeric nanoparticles bearing eOD-GT8, a germline-targeting HIV immunogen, and IL-21, a canonical GC cytokine. DNA delivery of these nanoparticle immunoadjuvant complexes (GT8-IL-21-NICs) drives improved serum antibody titers and antigen-specific GC B cell responses in mice. Transcriptomic analysis of eOD-GT8-specific GC B cells demonstrates upregulation of selection-associated gene signatures with GT8-IL-21-NIC immunization. In mice harboring human bnAb precursor heavy and light chain genes, immunization with the GT8-IL-21-NIC leads to increased antibody diversity, clonal expansion, somatic hypermutation, and the acquisition of key antibody mutations. These results highlight IL-21 as a promising genetic adjuvant and demonstrate that NICs may be a valuable tool to improve antigen-specific GC responses and vaccine-induced immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.